All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

People Science wants to revamp the clinical research ecosystem for non-traditional medicines.

Why it matters: People raised a second seed round of $5.3 million led by Acre Venture Partners, CEOs Noah Craft and Belinda Tan tell Axios exclusively.

Other participants included Bluestein Ventures, Thia Ventures and Form Life Ventures, bringing the company's total funding to $8.5 million.

People will use the funds to hone its technology platform, hire more staff focused on customer growth and expand into nutrition.

As part of the funding, Acre managing partner Lucas Mann joins People's board of directors.

Craft predicts the company will raise its Series A this fall.

Context: While traditional pharmaceuticals have a clear, albeit slow, path to approval, alternative medicines are much more cumbersome to study — and People joins a nascent group of companies innovating in the space. 

Bolt founder Ryan Breslow last August pulled in $7.5 million in seed funding for his latest venture Love, which aims to gather real world evidence on homeopathic solutions, generic chemicals and non-substance based treatments.

How it works: Based in Los Angeles, People designs protocols, recruits participants, oversees and conducts studies to match regulatory goals of clients including consumers, digital health companies and researchers.

Tan and Craft say the company's core differentiation strategy is its focus on enabling individuals to answer the question: Does this alternative medicine work for me?

The company's platform links patients, doctors and scientists to help test alternative therapies including psychedelic medicines, nutrition-based approaches, cannabis and the microbiome.

People's proprietary data collection tool, called CHLOE (Consumer Health Learning and Organizing Ecosystem) is an app for research participants.

The backstory: Tan and Craft previously cofounded and led Science 37, a decentralized clinical trial technology company that in 2021 went public through a $1 billion SPAC deal.

State of play: The company began running sponsored clinical studies late last year and hopes to make the app available to the public without a need to be enrolled in an existing study later this year.

"We want to empower people to be the scientist, to design their own studies and learn what works and what doesn't," Tan says.

While randomized controlled trials (RCTs) remain the gold standard for drug development, recent FDA guidance encourages researchers to also incorporate real-world evidence.

The intrigue: There's a big difference between anecdotal data based on individual experiences and rigorous clinical research, and People will need to get from one to the other. 

"This makes data collection and observational note-taking accurate and transmissible to other scientists," says Craft.

What's next: "We’d like for this to be a massively scaled software tool that goes global," Tan says.

Exclusive: Science 37 alums launch psychedelic research platform

The startup raised $5M led by Acre Venture Partners.

Illustration of a large cap mushroom inside of a pill bottle. 

Health tech deals

People Science wants to revamp the clinical research ecosystem for non-traditional medicines.Why it matters: People raised a second seed round of $5.3 million led by Acre Venture Partners, CEOs Noah Craft and Belinda Tan tell Axios exclusively.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

boulder

detroit

kansas-city

columbus

austin

dallas

atlanta

washington-dc

nw-arkansas

chicago

indianapolis

nashville

richmond

colorado-springs

houston

san-francisco

seattle

boston

des-moines

salt-lake-city

philadelphia

denver

phoenix

new-orleans

miami

twin-cities

raleigh

san-antonio

portland

san-diego

tampa-bay

cleveland

huntsville

pittsburgh

axios-local

axios-pro

axios-live

the-axios-show

Exclusive: Science 37 alums launch psychedelic research platform

What to read next